Zum Inhalt springen

Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

— VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (?150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT — — EddingPharm Now Working to Prepare for National Reimbursement and Drug Listing (NRDL)… Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)

A Chinese probe with samples from the far side of the moon has landed on Earth

It was launched into space by the Changcheng 5 launch vehicle. BEIJING. China’s Chang’e 6 probe landed on Earth on Tuesday with rock and soil samples from the little-explored far side of the moon. The probe landed in northern China on Tuesday afternoon local time. Beijing expects the samples to include 2.5 million-year-old volcanic rocks,… A Chinese probe with samples from the far side of the moon has landed on Earth

Belite Bio to Present at the JonesHealthcare Seaside Summit

Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that Dr. Nathan Mata, Chief Scientific Officer of Belite Bio, will participate in the JonesHealthcare Seaside Summit in Encinitas,… Belite Bio to Present at the JonesHealthcare Seaside Summit

Epidermolysis Bullosa: Symptome und Ursachen

Epidermolysis Bullosa (EB), auch als „Schmetterlingskrankheit“ bekannt, ist eine genetische Erkrankung, die dazu führt, dass sich leicht Blasen (Bullae) auf der Haut und den Schleimhäuten bilden. Es gibt verschiedene Arten dieser Krankheit, und jede Art weist unterschiedliche Symptome und Schweregrade auf. Hier sind einige wichtige Punkte zur Schmetterlingskrankheit … Arten der Schmetterlingskrankheit: Die Schmetterlingskranke… Was ist Epidermolysis Bullosa, was sind ihre Symptome und was sind die Ursachen?

US-Behörden warnen vor Denguefieber

Die Weltgesundheitsorganisation gab im April bekannt, dass die Zahl der Fälle von Denguefieber (Knochenbruchfieber), das durch das Denguevirus verursacht wird, in den letzten Jahren weltweit stark zugenommen hat, von rund 505.000 Fällen im Jahr 2000 auf 5,2 Millionen im Jahr 2019. Die Gesundheitsbehörden Puerto Ricos erklärten Denguefieber im März zum öffentlichen Gesundheitsnotstand. In einer gestern… US-Behörden warnen vor Denguefieber! – Nachrichten

Cybersicherheitsinitiative der Europäischen Union

Die Debatte darüber, ob das EU-Cybersicherheitszertifizierungssystem nicht große Technologieunternehmen diskriminieren sollte, nimmt zu. 26 Industrieverbände in Europa haben gewarnt, dass die von der EU vorgeschlagene Cybersicherheitszertifizierungsverordnung für Cloud-Dienste (EUCS) große Technologieunternehmen wie Amazon, Google und Microsoft nicht diskriminieren sollte. Die EU-Kommission, die EU-Cybersicherheitsagentur ENISA und die EU-Länder sollen am Dienstag über die Verordnung diskutieren, die… Cybersicherheitsinitiative der Europäischen Union

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company developing mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to new employees. On July 1, 2024, the Company issued to these employees options to purchase an aggregate of… Cartesian Therapeutics Announces New Employment Inducement Grants

Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed Kymera that it… Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

QIAGEN to enhance the identification of human remains of Indigenous people and African Americans

Partnership with University of Montana drives the implementation of next-generation sequencing and forensic investigative genetic genealogy in identifying human remains // QIAGEN provides instruments, kits and training for building the first Indigenous-owned DNA database and identifying African American human remains // Collaboration underlines QIAGEN’s leading position in the use of next-generation sequencing for forensic applications… QIAGEN to enhance the identification of human remains of Indigenous people and African Americans

Chinese AI developed CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer’s Disease

DP Technology, an „AI for Science“ paradigm-driven company, today announced the nomination of DPT0416, a novel CNS penetrable small molecule targeting Lp-PLA2, as a preclinical candidate for the treatment of Alzheimer’s disease (AD). AD is the most frequent cause of dementia (60%~70%), affecting approximately 57 million people worldwide. Neurovascular dysfunction is an early and predominant event in AD development, independent of classic amyloid pathology. Lp-PLA2 is a phospholipase secreted primarily by inflammatory cells, including peripheral macrophages and CNS microglia. It hydrolyzes oxidized phospholipids typically on low-density lipoprotein (LDL), producing lysophosphatidylcholine (lysoPC) and other potent proinflammatory factors. LysoPC is a key inflammatory mediator on vascular endothelial cells, causing vascular pathology including vessel leakage and BBB damage. The inhibition of Lp-PLA2 by Rilapladib significantly slowed down AD progression and repaired BBB damage in a Phase IIa trial. DPT0416 is a novel CNS-penetrable… 

more »Chinese AI developed CNS Penetrable Lp-PLA2 Inhibitor for Alzheimer’s Disease